Bibliography
- Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world–a growing challenge. N Engl J Med 2007;356:213-5. Erratum in: N Engl J Med 2007 Mar 1;356:973
- Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147(6):386-99. Erratum in: Ann Intern Med 2007;147:887
- Villacorta L, Schopfer FJ, Zhang J, et al. PPARgamma and its ligands: therapeutic implications in cardiovascular disease. Clin Sci (Lond) 2009;116:205-18
- Acharya D, Falik R. Cardiovascular effects of thiazolidinediones: a review of the literature. South Med J 2009;102:51-6
- Grant RW, Buse JB, Meigs JB. Quality of diabetes care in US academic medical centers: low rates of medical regimen change. Diabetes Care 2005;28:337-442
- UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44(11):1249-58. Erratum in: Diabetes 1996 Nov;45:1655
- Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007;117:24-32
- Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2:1300-4
- Tolhurst G, Reimann F, Gribble FM. Nutritional regulation of glucagon-like peptide-1 secretion. J Physiol 2009;587:27-32
- Theodorakis MJ, Carlson O, Michopoulos S, et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 2006;290:E550-9
- Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987;79:616-19
- Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988;123:2009-13
- Schirra J, Sturm K, Leicht P, et al. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 1998;101:1421-30
- Farret A, Lugo-Garcia L, Galtier F, et al. Pharmacological interventions that directly stimulate or modulate insulin secretion from pancreatic beta-cell: implications for the treatment of type 2 diabetes. Fundam Clin Pharmacol 2005;6:647-56
- Brubaker PL, Drucker DJ. Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004;145:2653-9
- Nauck MA, Ratner RE, Kapitza C, et al. Treatment with the human once-weekly GLP-1 analogue taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes mellitus inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 2009: published online before print April 14, 2009, doi: 10.2337/dc08-1961
- Kapitza C, Klein O, Obach R, et al. Long acting human GLP-1 analogue R1583: safety, pharmacokinetic and pharmacodynamic properties after a single administration in subjects with type 2 diabetes. Diabetes 2008;57(Suppl 1):506-P [abstract]
- Available from: http://www.healthfinder.gov/news/newsstory.aspx?docID=625741 [Last acecced 22 April 2009]
- Ahrén B. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. Expert Opin Emerg Drugs 2008;4:593-607
- Gallwitz B. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. IDrugs 2008;5:906-17
- Ratner R, Nauck M, Asnaghi V, et al. Safety an tolerability of high doses of the long acting, human GLP-1 analogue R1583 in diabetic subjects treated with metformin: a Double-Blind, Placebo-Controlled Phase-2 Study. Diabetes 2008;57(Suppl 1):P A3 [abstract]
- Kapitza C, Heise T, Klein O, et al. BIM51077, a novel GLP-1 analog, achieves sustained improvement in blood glucose control over 28 days of treatment. American Diabetes Assosiation. 66th Scientific Sessions; 2006:500-P [poster]
- Kapitza C, Klein O, Obach R, et al. Long acting human GLP-1 analogue R1583: safety, pharmacokinetic and pharmacodynamic properties after a single administration in subjects with type 2 diabetes. American Diabetes Assosiation 68th Scientific Sessions; 2008:506-P [abstract]
- Kapitza C, Heise T, Klein O, et al. BIM51077, a novel GLP-1 analog, showed linear PK and dose-response relationship over 7 days of treatment. American Diabetes Assosiation. 66th Scientific Sessions; 2006:2019-PO [abstract]
- Balena R, Ratner R, Berria R, et al. Eight weeks of treatment with the long acting, human GLP-1 analogue R1530 improves glycemic control and lowers body weight in subjects with Type 2 Diabetes Mellitus (T2DM) treated with metformin: a Double-Blind Placebo-Controlled Phase 2 Study. Diabetes 2008;57(Suppl 1):506-P [abstract 33]
- Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;6:1487-93
- Garber A, Henry R, Ratner R, et al.; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81
- Steinberger J, Daniels SR, Eckel RH, et al.; American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Circulation 2009;119:628-47
- Paris M. 2008: the end of rimonabant story. Ann Pharm Fr 2009;67:167-8
- Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 2008;93:3703-16
- Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7
- Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-87
- Rosenstock J, Brazg R, Andryuk PJ, et al.; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556-68
- Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43
- Deacon CF, Holst JJ. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv Ther 2009. Published online May 14 2009
- Göke B, Hershon K, Kerr D, et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Horm Metab Res 2008;40:892-5
- Scherbaum WA, Schweizer A, Mari A, et al. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*. Diabetes Obes Metab 2008;8:675-82
- Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;1:82-90
- Thomsen C, Storm H, Holst JJ, Hermansen K. Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes. Am J Clin Nutr 2003;77:605-11
- Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTPPE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine. Drugs R D 2008;9:131-5
- Miyauchi S, Hirasawa A, Iga T, et al. Distribution and regulation of protein expression of the free fatty acid receptor GPR120. Naunyn Schmiedebergs Arch Pharmacol 2009;379:427-34